Skip to main content
. 2019 May 9;44:311–321. doi: 10.1016/j.ebiom.2019.05.003

Fig. 2.

Fig. 2

miR-567 suppresses GC cell proliferation and increases drug sensitivity in vitro and in vivo. FACS assays (A) and EdU incorporation assays (B) of GC cells were performed after transfected with miR-567 mimic or anti-miR-567, Student's t-test, mean ± SD, *P < .05; **P < .01; ***P < .001. (C&D) Dose-response curves of MGC803 and BGC823 treated with 5-FU for 36 h or oxaliplatin for 24 h, the cells were previously transfected with miR-NC, miR-567, anti-miR-NC or anti-miR-567. Parametric generalized linear model with random effects, Student's t-test, mean ± SD, *P < .05; **P < .01; ***P < .001. (E) Western blot experiments were used to analyse the expression of c-casp3, casp3, c-PARP, PARP, c-casp9, casp9, p21, CDK4, CDK6 and CyclinD1 after miR-567 knockdown and overexpression in MGC803 and BGC823 cells. (F) In vivo image detection of the xenograft tumour growth. Growth curve was measured and drawn, *P < .05. The tumour sections were under IHC staining using antibodies against Ki-67. Quantification of Ki67 staining of the xenograft tumours (right). ***P < .001.